BioViva’s aims to be an advanced medicinal product access platform. To this end BioViva is committed to the following:
An architecture of participation, means that both patients and biotech companies will be able to enhance and extend our platform for testing consensual gene and cell therapies.
Low barriers to human trails, means that our platform is committed to provide biotech companies, doctors networks, and patients with fast and efficient access to each other.
Interoperability, means that our platform will be continuously collect and monitor human data and any changes in biomarkers of aging due to treatments. We will utilize the latest machine learning algorithms to validate these findings, and find the optimal combinatorial regimens for anti-aging treatments. We will make our insights available to all users of our platform.
“Lock-in” to our platform will come not because we hoard the data, but because doctor networks, biotech companies, and patients will come to depend on the benefits from our services, and insights from our platform to accelerate the therapies to treat aging.